Correlations between Psoriasis and Inflammatory Bowel Diseases

Skroza, Nevena; Proietti, Ilaria; Pampena, Riccardo; Viola, Giorgio La; Bernardini, Nicoletta; Nicolucci, Francesca; Tolino, Ersilia; Zuber, Sara; Soccodato, Valentina; Potenza, Concetta

doi:10.1155/2013/983902

Cited by 88 publications

(92 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of extra-articular manifestations reported as AEs in our study was low and consistent with expected rates in AS. IL-17A has been reported to have either a pathogenic or a protective role in Crohn's disease 46 47. The incidence of Crohn's disease in the present study (0.8 per 100 patient-years of secukinumab exposure) compares with reported rates of 0.2–1.3 per 100 patient-years for TNF inhibitors in the AS population 48…”

Section: Discussionsupporting

confidence: 53%

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

et al. 2016

View full text Add to dashboard Cite

Objective To evaluate the effect of secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic changes through 2 years in patients with ankylosing spondylitis (AS). Methods In the phase III MEASURE 1 study, patients were randomised to receive intravenous secukinumab 10 mg/kg (at baseline, week 2 and week 4) followed by subcutaneous secukinumab 150 mg (intravenous 150 mg; n=125) or 75 mg (intravenous 75 mg; n=124) every four weeks, or matched placebo (n=122). Placebotreated patients were re-randomised to subcutaneous secukinumab 150 or 75 mg from week 16. Clinical efficacy assessments included Assessment of SpondyloArthritis international Society 20 (ASAS20) response rates through week 104. Radiographic changes at week 104 were assessed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). Results 97 (77.6%) and 103 (83.1%) patients in the intravenous 150 mg and intravenous 75 mg groups, respectively, completed week 104. In the full analysis set (intent-to-treat), ASAS20 response rates at week 104 were 73.7% and 68.0% in the intravenous 150 mg and intravenous 75 mg groups, respectively. Among patients with evaluable X-rays who were originally randomised to secukinumab (n=168), mean change in mSASSS from baseline to week 104 was 0.30±2.53. Serious adverse events were reported in 12.2% and 13.4% of patients in the 150 mg and 75 mg groups, respectively. Conclusions Secukinumab improved AS signs and symptoms through 2 years of therapy, with no unexpected safety findings. Data from this study suggest a low mean progression of spinal radiographic changes, which will need to be confirmed in longer-term controlled studies. Trial registration number NCT01358175.

show abstract

Section: Discussionsupporting

confidence: 53%

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The term comorbidity, first used by Feinstein 100 regarding patients with rheumatic fever, defined as a " proven pathogenic mechanism" 101,102 and exemplified in the description of psoriasis and inflammatory bowel disease 103 , is now widely used in psychiatry 104 . There are, however, varying definitions in use 105,106 , including within the GTS literature.…”

Section: Shared Genetic Basis With Other Neuropsychiatric and Neurolomentioning

confidence: 99%

Gilles de la Tourette syndrome

Robertson

Eapen

Singer

et al. 2017

Nat Rev Dis Primers

296

244

View full text Add to dashboard Cite

The unstructured abstract of 200 words maximum should summarize the main points of the article. All information mentioned in the abstract must be addressed somewhere in the main article. The abstract should not contain references or display item citations. Gilles de la Tourette Syndrome (GTS), a reasonably common disorder, has had a long, tortuous and somewhat controversial history. First and well described in the 18th century 1,2 , the main features of GTS have, however, remained fairly constant. The core diagnostic features are multiple motor and one or more vocal (phonic) tics lasting for over a year. In addition, almost pathognomic, but not necessary, features described in the early documentations include coprolalia (involuntary, inappropriate swearing), and echophenomena (copying behaviours), as well as many co-morbidities and psychopathologies 3 . Introduction [suggested 500 words, is 544 words -8 refs] Mary Robertson Thoughts for Mary -Your word count when combining sections 1 and 2 is 1001 (1000 limit)-so OKGTS was originally described in France and the majority of early literature came from and standardised schedules such as diagnostic confidence, measurement of severity, QoL, and assessment of both co-morbidities and co-existent psychopathologies are currently available.Large international collaborative consortia are engaged in studies exploring aetiological factors in particular, and some international treatment studies are also underway. Perhaps as a result of earlier small patient numbers, the treatment trials have given good clues to management, but unsurprisingly systematic reviews and meta-analyses have been hampered, giving disappointing, if not unexpected, results. Intriguingly medications from the typical NRDP -Gilles de la Tourette Syndrome 3 antipsychotic family including haloperidol, which first had documented success in 1961 6,7 are still being used, although successive generations of "atypicals" are currently more in vogue,as are medications such as alpha-2-adrenergic agonists. Interestingly, haloperidol remains the only medication prescribed on licence in many parts of the world. In contrast to disorders such as ADHD, in which it is clear which treatments work and which do not require further study 8 , a variety of treatment studies in GTS are still being undertaken, including using other medications (trying to improve efficacy and reduce side effects), behavioural therapies, deep brain stimulation (for refractory cases), and other more "alternative" methods such as "orthotics" (teeth braces). The GTS community has to first agree on how common GTS is and then seek funding for research in the areas of major importance.2. Epidemiology [suggested 500 words, is 444 words, 6 additional refs] Mary Robertson GTS was for many years thought to be not only very rare, but a bizarre curiosity, with sporadic case reports peppering the literature. The belief that GTS was uncommon at the very least was held by many until Comings 9 controversially suggested that GTS occurred in between 0.66% and...

show abstract

“…For example, the IL‐23 pathway mediates microbial defence and intestinal inflammation, and genes such as the IL‐23 receptor ( IL23R ) and IL12B have been associated with CD and UC . Notably, these and numerous other IBD‐related genes, including the tyrosine protein kinase 2 ( TYK2 ), Janus kinase 2 ( JAK2 ) and signal transducer and activator of transcription 3 ( STAT3 ) genes, are also associated with psoriasis …”

mentioning

confidence: 99%